Saturday 20 January 2018 photo 5/5
|
Dpwg guidelines: >> http://nrn.cloudz.pw/download?file=dpwg+guidelines << (Download)
Dpwg guidelines: >> http://nrn.cloudz.pw/read?file=dpwg+guidelines << (Read Online)
cpic conservation
cpic guidelines warfarin
royal dutch pharmacists association
dutch pharmacogenetics working group
cpic pharmacogenomics
cpic guidelines cyp2d6
cpic federal government
capital planning and investment control
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on TPMT genotype [Article:21412232]. They recommend selecting an alternative drug or reducing the initial dose for patients carrying inactive alleles.
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for omeprazole based on CYP2C19 genotype [Article:21412232]. For the CYP2C19 UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for capecitabine (a fluorouracil prodrug) based on DPYD genotype [Article:21412232]. They recommend that an alternate drug be used for poor metabolizer patients, and a reduced dose or
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype [Article:21412232]. They recommend reducing the dose for *28 homozygous patients receiving more than 250 mg/m2.
The Dutch Pharmacogenetics Working Group (DPWG) was established in 2005 by the Royal Dutch Pharmacist's Association (KNMP). The DPWG is multidisciplinary and includes clinical pharmacists, physicians, clinical pharmacologists, clinical chemists, epidemiologists, and toxicologists. The objectives of the DPWG are:.
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tamoxifen based on CYP2D6 genotypes [Article:21412232]. For PM and IM genotypes, they recommend considering using aromatase inhibitors for postmenopausal women due to increased
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype [Article:21412232]. They recommend either selecting another drug or dose reduction for poor and intermediate metabolizer patients, with dose
PharmGKB annotates PGx-based drug dosing guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group (DPWG), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) and
The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for hormonal contraceptives for systemic use based on Factor V Leiden (FVL, or F5) genotype [Article:21412232]. They suggest that in individuals who carry the Factor V Leiden allele and have a
The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends to select an alternative drug or monitor amitriptyline and nortriptyline plasma concentration for patients who are CYP2D6 poor or ultrarapid metabolizers. Reduce the initial dose for patients who are intermediate metabolizers or select an
Annons